WO2022126525A1 - Marqueur prnp de maladie neurodégénérative et application associée - Google Patents

Marqueur prnp de maladie neurodégénérative et application associée Download PDF

Info

Publication number
WO2022126525A1
WO2022126525A1 PCT/CN2020/137308 CN2020137308W WO2022126525A1 WO 2022126525 A1 WO2022126525 A1 WO 2022126525A1 CN 2020137308 W CN2020137308 W CN 2020137308W WO 2022126525 A1 WO2022126525 A1 WO 2022126525A1
Authority
WO
WIPO (PCT)
Prior art keywords
prion protein
alzheimer
gene
disease
sirna
Prior art date
Application number
PCT/CN2020/137308
Other languages
English (en)
Chinese (zh)
Inventor
陈宇
屈雪琪
林力
陈岳文
Original Assignee
深圳先进技术研究院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 深圳先进技术研究院 filed Critical 深圳先进技术研究院
Priority to PCT/CN2020/137308 priority Critical patent/WO2022126525A1/fr
Publication of WO2022126525A1 publication Critical patent/WO2022126525A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Definitions

  • the invention belongs to the field of biological detection, in particular to a neurodegenerative disease marker Prnp and its application.
  • AD Alzheimer's disease
  • AD Association in 2018, there are currently at least 50 million patients worldwide, and this number is expected to reach 152 million by 2050.
  • China has now become the country with the largest number of Alzheimer's patients.
  • AD has become an urgent medical and social problem to be solved.
  • AD Alzheimer's disease
  • the current diagnostic methods of AD are mainly combined diagnosis, including: neuropsychological assessment, cognitive impairment test; brain senile plaque and Tau protein PET scan; brain magnetic resonance (MRI) and cerebrospinal fluid (CSF) markers, ⁇ - Amyloid, phosphorylated tau protein detection, etc. [1].
  • MRI brain magnetic resonance
  • CSF cerebrospinal fluid
  • AD mild intellectual impairment
  • MCI mild intellectual impairment
  • Early clinical diagnosis and subsequent treatment of AD are the key points to solve AD symptoms [2-4].
  • early molecular screening techniques for AD include positron emission tomography (PET) and cerebrospinal fluid A ⁇ molecular level detection.
  • PET positron emission tomography
  • cerebrospinal fluid A ⁇ molecular level detection The former requires a certain dose of radioactive substances to be injected into the subject; cause surgical infection.
  • the reliability of these diagnostic techniques for the early diagnosis of AD is also not stable, so it is difficult to be used for early AD screening. Therefore, the development of new biomarkers for early diagnosis of AD is one of the important directions for AD diagnosis and treatment in the future, and there is still a long way to go for new biomarkers to be used in clinical applications.
  • the APP/PSEN1 mouse model (hereinafter referred to as the AD mouse model) is one of the ideal animal models for simulating AD disease, and is widely used in the study of AD pathogenic mechanisms [5]. Numerous studies have confirmed that neuronal synaptic plasticity plays an important role in neurodegenerative diseases (eg AD, PD, HD, etc.) in living organisms. According to the difference of local translation protein expression in synaptic sites, the present invention screens out molecular biomarkers for AD early disease diagnosis, which can realize early detection, early intervention and early treatment, thereby delaying the course of disease and reducing mortality.
  • AD neurodegenerative diseases
  • PrP Prion protein
  • Prnp Prion protein
  • the C129 and C219 codon polymorphisms of Prnp gene are associated with the occurrence and development of neurodegenerative diseases. Studies have confirmed that the PrP C protein encoded by the Prnp gene has a high affinity for A ⁇ , and mediates the inhibition of long-term potentiation (LTP, which plays an important role in inducing synaptic toxicity [6,7].
  • AD insidious onset
  • One aspect of the present invention is to provide a composition for early assessment of Alzheimer's disease risk, the composition comprising a composition at the level of a prion protein-encoding gene in a subject's brain neuron synapses.
  • the level of the prion protein-coding gene refers to the composition of the mRNA level of the prion protein-coding gene.
  • the composition for detecting the mRNA level of the prion protein-encoding gene is selected from the combination of primers and or probes for detecting the NM_001278256.1 gene fragment.
  • composition for detecting the miRNA level of the prion protein-encoding gene is selected from the following primer compositions:
  • Another aspect of the present invention is to provide a kit comprising the above composition for detecting the level of a prion protein-encoding gene.
  • the kit further comprises reagents for transcriptome detection and/or reagents for quantitative reverse transcription PCR.
  • the kit further includes a detection composition for housekeeping genes.
  • the housekeeping gene in the kit is selected from GAPDH and or HPRT.
  • the detection primer composition of described housekeeping gene is:
  • the primer composition for detecting GAPDH is:
  • the primer composition for detecting HPRT is:
  • Another aspect of the present invention is to provide the use of the above-mentioned composition or kit for detecting RNA level in the preparation of a reagent for detecting Alzheimer's disease risk assessment.
  • the Alzheimer's disease risk assessment is an early Alzheimer's disease risk assessment.
  • the early risk assessment of Alzheimer's disease is an assessment performed before the occurrence of amyloid in the subject.
  • Yet another aspect of the present invention provides a method for predicting Alzheimer's disease risk, the method comprising the steps of:
  • the method for predicting the risk of Alzheimer's disease further comprises the step of comparing the expression level of the prion protein-encoding gene in the brain synapse of the subject with a negative control or with a normal value range .
  • the detection method in the step 2) is selected from using transcriptome detection and or quantitative reverse transcription PCR.
  • the above-mentioned composition or kit of the present invention is used in the step 2).
  • the expression level of the prion protein-encoding gene in the brain synapse is higher than the negative control or the normal value range, it is considered to be at risk of Alzheimer's disease.
  • the method for predicting the risk of Alzheimer's disease is a method for predicting the risk of Alzheimer's disease at an early stage, and the early stage means that amyloid does not appear in the brain of the subject.
  • Another aspect of the present invention provides a drug for reducing the risk of Alzheimer's disease, the drug comprising an inhibitor of a gene encoding a prion protein.
  • the inhibitor of the prion protein encoding gene is used to inhibit the transcription, translation and expression of the prion protein encoding gene.
  • Another aspect of the present invention provides the use of an inhibitor of a gene encoding a prion protein in the preparation of a medicament for treating Alzheimer's disease.
  • Another aspect of the present invention provides the use of an inhibitor of a prion protein-encoding gene in the preparation of a medicament for repairing neuronal synapses and or increasing the density or volume of neuronal dendritic spines.
  • the inhibitor of the prion protein encoding gene is selected from the shRNA, siRNA, dsRNA, miRNA, antisense nucleic acid, siRNA targeting sequence or iRNA targeting sequence of the prion protein encoding gene; or can express or Form the construct of described shRNA, siRNA, dsRNA, miRNA, antisense nucleic acid, described siRNA sequence is shown as SEQ ID No.13 or SEQ ID No.14.
  • Another aspect of the present invention provides the use of neuronal cells with up-regulated prion protein-encoding genes in the preparation of drugs for screening and repairing neuronal synapses and/or dendritic spines.
  • the present invention discovers the Prnp gene. Compared with traditional detection methods, gene diagnosis is more timely, specific, convenient and sensitive.
  • AD Early diagnosis of AD can be achieved, thereby providing guidance for early intervention in AD, thereby delaying AD symptoms and prolonging the life of patients.
  • Figure 1 is a volcano plot of neurodegenerative disease-related genes obtained by RNA-seq analysis of brain tissue synapses. The volcano plot reveals the differential gene distribution between littermate wild-type and AD mice in the SD group.
  • Figure A shows the same 3-month-old Gene differences between litters of wild-type and AD mice;
  • panel B shows the gene differences between 6-month-old littermates of wild-type and AD mice.
  • Figure 2 is a heat map of neurodegenerative disease-related gene expression obtained by RNA-seq analysis of brain tissue synapses.
  • the differential expression results of genes related to AD disease are marked with grid fills represent up-regulation, and those that are not marked represent down-regulation.
  • Different gray levels represent different degrees of difference, and gray levels that are approximately darker represent higher degrees of difference.
  • Figure 3 shows the data classification analysis.
  • Picture A shows the genes with FDR (false discovery rate) ⁇ 0.01, in which genes with expression changes greater than 2 were found. These genes were classified, and 12 genes with significant differences were enriched in energy metabolism-related pathways; it could be found that they were significantly associated with AD disease signaling pathways, of which the core gene was Prnp.
  • 1 is the binding of amyloid beta protein
  • 2 is the negative regulation of dendritic spines
  • 3 is the binding of copper ions
  • 4 is the regulation of age-related behavioral decline
  • 5 is the regulation of the entry of calcium ions through the cell membrane
  • 6 is the Protein binding
  • 7 is the detoxification of copper ions
  • 8 is the protection of glial cells
  • 9 is myelin sheath
  • 10 is the regulation of chemical synapses.
  • Figure 4 Distribution of Prnp in mouse cortex and synaptosome (SD) after validation by qPCR. Differential expression of Prnp between wild-type and AD-type fractions. Picture A shows the expression of Prnp in the cortex and hippocampus of 3-month-old mice; Picture B shows the expression of Prnp in SD components of 3-month-old and 6-month-old mice.
  • FIG. 5 shows the calcium transduction of shPrnp in primary neurons.
  • shPrnp can restore the density of dendritic spines and synaptosomes in primary neurons of rat hippocampus at 14 days.
  • the AD mouse strain used came from the Jackson Laboratory, and was bred and raised in the SFP animal room of the Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences. The operation was in line with animal ethics and experimental standards; the anatomy and other related surgical instruments were purchased from Ruiward; the ultracentrifuge and The supporting rotor and centrifuge tube were purchased from Beckman; the gradient centrifuge was from Thermo Fisher Scientific; the TRIzol TM Reagent was from Invitrogen; the RNA-seq service and the preliminary data processing service were provided by Novogene; phosphate buffered saline (PBS), etc. Produced by Gibco Company; SYBR Green and corresponding qPCR detection instruments are from Thermo Fisher Scientific Company.
  • the 3-month-old (3M) and 6-month-old (6M) littermates of wild-type (WT) and transgenic AD mice (AD) were anesthetized with isoflurane (gas), and then quickly decapitated with scissors after menstruation. , place the head on ice, and rapidly dissociate the cerebral cortex and isolate the cerebral cortex and hippocampus of the mouse.
  • the isolated tissue was washed twice in DPBS containing 4 U/mL of protease inhibitor and RNase inhibitor to obtain a cerebral cortex tissue sample.
  • tissue homogenate balance solution containing protease inhibitors and RNase inhibitors
  • 2 mL of cerebral cortex was taken and homogenized in the same tissue homogenate balance solution.
  • Trizon method For detailed methods, please refer to the instructions for use of TRIzol TM Reagent from Invitrogen as follows:
  • Homogenization treatment Grind the tissue or cells in liquid nitrogen, add 1 mL of TRIzol per 50-100 mg of tissue, and perform homogenization treatment with a homogenizer. The sample volume should not exceed 10c/o of the TRIzol volume.
  • RNA is mainly in the aqueous phase, and the volume of the aqueous phase is about 60c/o of the TRIzol reagent used.
  • RNA in the aqueous phase was precipitated with isopropanol. Add 0.5 mL of isopropanol for every 1 mL of TRIzol used, and leave at room temperature for 10 minutes.
  • RNA pellet with 75c/o ethanol. Add at least 1 mL of 75c/o ethanol for every 1 mL of TRIzol used. Centrifuge at 2-8°C at no more than 7500 ⁇ g for 5 minutes, and discard the supernatant.
  • RNA precipitate for about 5 to 10 minutes. Do not vacuum centrifuge to dry, as excessive drying will greatly reduce the solubility of RNA. Add 25-200 ⁇ L of RNase-free water or 0.5c/o SDS, pipette several times with a pipette tip, and place at 55-60°C for 10 minutes to dissolve the RNA. Do not use SDS solution if RNA is used for digestion. RNA can also be dissolved in 100c/o of deionized formamide and stored at -70°C.
  • RNAs from different sources obtained in Example 3 were reverse transcribed into cDNAs, and the synthesized cDNAs were subjected to quantitative RT-PCR detection and transcriptome sequencing.
  • the housekeeping genes used were GAPDH and HPRT.
  • the amplified sequence of the Prnp gene is NM_001278256.1;
  • Prnp gene amplification primer is F:accagaacaacttcgtgcac SEQ ID No.1
  • the amplified sequence of GAPDH gene is NM_008084.3;
  • GAPDH gene amplification primer is F: TCAACAGCAACTCCCACTCTTCCA SEQ ID No.3
  • the amplified sequence of HPRT gene is NM_013556.2;
  • HPRT gene amplification primer is F: GGAGTCCTGTTGATGTTGCCAGTA SEQ ID No.5
  • the cDNA derived from brain neuron synapse samples was amplified and sequenced by RNA-seq, and the data was analyzed by bioinformatics, including volcano map, heat map, and gene enrichment analysis (GO analysis).
  • bioinformatics including volcano map, heat map, and gene enrichment analysis (GO analysis).
  • FDR false discovery rate
  • gene enrichment analysis was performed on the genes whose relative expression difference was more than 2 times.
  • Significantly different genes were enriched in pathways related to energy metabolism and were significantly associated with neurodegenerative diseases.
  • qRT-PCR was used to verify the difference of Prnp gene expression between wild-type mice and AD mice at different time periods with RNA derived from brain neuron synapse samples, cerebral cortex tissue and hippocampus tissue.
  • AD mouse brain tissue Primary culture of neurons in vitro was performed.
  • the slides with neurons cultured on the inner surface of the 24-well plate were placed in equilibrated 1.5 mL DMEM, and put into a 7.5% CO 2 incubator to starve for 1 hour.
  • the required amount of plasmid and 5 ⁇ L of 2M CaCl 2 were added to water to form a 50 ⁇ L system.
  • transfection solution dropwise evenly to the glass slides in the wells, put them into a 7.5% CO 2 incubator and let stand for about 15 minutes (depending on the size of calcium phosphate crystals). After washing twice with 1 mL of DMEM, the slides were placed in the neuron maintenance medium, returned to the 5% CO 2 incubator, and the medium was half-changed after 1 hour.
  • the experiment was divided into 4 groups, and the plasmids were selected from pSUPER vector plasmid (blank group), pSUPER vector plasmid transfected with scr-Prnp (negative control), SUPER vector plasmid transfected with shPrnp#1p and transfected with shPrnp#2. pSUPER vector plasmids, respectively.
  • the plasmid construction method is to use shRNA primers to co-incubate with the pSUPER vector plasmid to obtain a plasmid that generates siRNA in the transfected cells.
  • the primers used for each group of plasmids are as follows:
  • siRNA targeting sequences obtained from shPrnp 1# and shPrnp 2# obtained by sequencing are:
  • RRNP siRNA 1# CCTGTGATCCTCCTCATCT SEQ ID No.13
  • RNA-seq detection is aimed at the analysis of brain neuron synapses (SD).
  • SD brain neuron synapses
  • Prnp gene functions were mainly enriched in: A ⁇ recognition and binding, dendritic spine regulation, metal ion recognition and transport, age-related neurodegeneration Sexual disease regulation, etc. ( Figure 3). Therefore, Prnp can serve as a candidate biomarker for early diagnosis of neurodegenerative diseases.
  • the qRT-PCR results are shown in Figure 4.
  • the experimental results show (Figure 4A) that there is no significant difference in the expression of Prnp in the cerebral cortex of 3-month-old wild-type mice and AD mice.
  • the comparison of hippocampal tissues of 3-month-old wild-type mice and AD mice, and the comparison of cerebral cortex and hippocampal tissues of 6-month-old wild-type mice and AD mice showed that the expression of Prnp in AD mice was relatively high.
  • the expression level in wild-type mice was significantly reduced.
  • the results showed (Fig. 4B) that the expression of Prnp in synapses of 3-month-old AD mice was significantly higher than that of wild-type mice, while 6-month-old mice did not show this difference.
  • Dendritic spines are protruding structures on the dendritic trunk of a neuron that serve as the main structure of the postsynaptic component in the synaptic structure. Dendritic spines are the most direct anatomical structures for synaptic connections and transmission, and the dynamic changes in their formation and degradation are widely regarded as hallmarks of synaptic plasticity.
  • Prnp gene is highly expressed in early Alzheimer's brain neurons and can be used as a marker for early Alzheimer's, which is consistent with the results of qPCR and RNA-seq.
  • the results of calcium phosphate transfection experiments in primary neurons also revealed the use of the Prnp gene as a target for early therapy. Knockdown of Prnp can restore the density and size of dendritic spines and synapses in neurons.
  • the dendritic spines and synapses in neurons have been shown to be associated with changes in synapses or dendritic spine morphology associated with Alzheimer's disease, and are important factors in neurodegenerative diseases.
  • the invention inhibits the expression of Prnp gene through the interference of RRNP siRNA 1# and 2#, so that the volume and number of dendritic spines and synapses in neurons become larger, and the reduction of Prnp expression can increase synaptic plasticity and improve dendritic spines.
  • the Prnp gene expression inhibitor can restore the density and thickness of dendritic spines and synapses, which in turn predicts the improvement and therapeutic effect of neurodegenerative diseases.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un produit pour diagnostiquer et traiter les maladies neurodégénératives en utilisant un gène codant pour la protéine prion (Prnp) comme cible, et une utilisation associée. Plus particulièrement, la présente invention concerne une composition pour l'évaluation précoce d'un risque de développer la maladie d'Alzheimer. La composition comprend un réactif pertinent pour détecter le niveau du gène codant pour la protéine prion dans les synapses des neurones du cerveau d'un sujet. La présente invention concerne également une utilisation de la composition pour évaluer le risque de développer la maladie d'Alzheimer. La présente invention concerne également l'utilisation d'un inhibiteur du gène codant pour la protéine prion dans la préparation d'un médicament destiné à traiter la maladie d'Alzheimer.
PCT/CN2020/137308 2020-12-17 2020-12-17 Marqueur prnp de maladie neurodégénérative et application associée WO2022126525A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2020/137308 WO2022126525A1 (fr) 2020-12-17 2020-12-17 Marqueur prnp de maladie neurodégénérative et application associée

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2020/137308 WO2022126525A1 (fr) 2020-12-17 2020-12-17 Marqueur prnp de maladie neurodégénérative et application associée

Publications (1)

Publication Number Publication Date
WO2022126525A1 true WO2022126525A1 (fr) 2022-06-23

Family

ID=82058824

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/137308 WO2022126525A1 (fr) 2020-12-17 2020-12-17 Marqueur prnp de maladie neurodégénérative et application associée

Country Status (1)

Country Link
WO (1) WO2022126525A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010019270A1 (fr) * 2008-08-14 2010-02-18 Isis Pharmaceuticals, Inc. Modulation de l'expression des prions
CN103255142A (zh) * 2012-02-21 2013-08-21 上海转基因研究中心 一种利用RNAi调控内源性朊蛋白表达的方法及其应用
WO2020123884A1 (fr) * 2018-12-13 2020-06-18 Goetzl Edward J Exosomes dérivés de neurones et leurs biomarqueurs pour le diagnostic, le pronostic et le traitement d'un traumatisme craniocérébral et de la maladie d'alzheimer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010019270A1 (fr) * 2008-08-14 2010-02-18 Isis Pharmaceuticals, Inc. Modulation de l'expression des prions
CN103255142A (zh) * 2012-02-21 2013-08-21 上海转基因研究中心 一种利用RNAi调控内源性朊蛋白表达的方法及其应用
WO2020123884A1 (fr) * 2018-12-13 2020-06-18 Goetzl Edward J Exosomes dérivés de neurones et leurs biomarqueurs pour le diagnostic, le pronostic et le traitement d'un traumatisme craniocérébral et de la maladie d'alzheimer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GIMBEL D. A., NYGAARD H. B., COFFEY E. E., GUNTHER E. C., LAUREN J., GIMBEL Z. A., STRITTMATTER S. M.: "Memory Impairment in Transgenic Alzheimer Mice Requires Cellular Prion Protein", THE JOURNAL OF NEUROSCIENCE, vol. 30, no. 18, 5 May 2010 (2010-05-05), US , pages 6367 - 6374, XP055944135, ISSN: 0270-6474, DOI: 10.1523/JNEUROSCI.0395-10.2010 *
LAURÉN JUHA; GIMBEL DAVID A; NYGAARD HAAKON B; GILBERT JOHN W; STRITTMATTER STEPHEN M: "Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers.", NATURE, vol. 457, no. 7233, 26 February 2009 (2009-02-26), London, pages 1128 - 1132, XP009120514, ISSN: 0028-0836, DOI: 10.1038/nature07761 *
SALAZAR SANTIAGO V., GALLARDO CHRISTOPHER, KAUFMAN ADAM C., HERBER CHARLOTTE S., HAAS LAURA T., ROBINSON SOPHIE, MANSON JEAN C., L: "Conditional Deletion of Prnp Rescues Behavioral and Synaptic Deficits after Disease Onset in Transgenic Alzheimer's Disease", THE JOURNAL OF NEUROSCIENCE, vol. 37, no. 38, 20 September 2017 (2017-09-20), US , pages 9207 - 9221, XP055944134, ISSN: 0270-6474, DOI: 10.1523/JNEUROSCI.0722-17.2017 *

Similar Documents

Publication Publication Date Title
Ge et al. Increased microglial exosomal miR-124-3p alleviates neurodegeneration and improves cognitive outcome after rmTBI
Phan et al. A myelin-related transcriptomic profile is shared by Pitt–Hopkins syndrome models and human autism spectrum disorder
Wang et al. Human microRNA (miR-20b-5p) modulates Alzheimer’s disease pathways and neuronal function, and a specific polymorphism close to the MIR20B gene influences Alzheimer’s biomarkers
Asai et al. Accelerated neurodegeneration and neuroinflammation in transgenic mice expressing P301L tau mutant and tau-tubulin kinase 1
Li et al. MicroRNA-574 is involved in cognitive impairment in 5-month-old APP/PS1 mice through regulation of neuritin
CN113383090A (zh) 诊断疾病状态的方法
CN106913876B (zh) miRNA-30a-5p在帕金森病检测、治疗、预后靶点的应用
Zhang et al. Ginsenoside Rf inhibits human tau proteotoxicity and causes specific LncRNA, miRNA and mRNA expression changes in Caenorhabditis elegans model of tauopathy
Ba et al. Does chronic sleep fragmentation lead to Alzheimer's disease in young wild-type mice?
Wu et al. Osteoblast-derived lipocalin-2 regulated by miRNA-96-5p/Foxo1 advances the progression of Alzheimer’s disease
CN114645086B (zh) 一种神经退行性疾病标志物Prnp及其应用
Wang et al. Calpain-2 mediates MBNL2 degradation and a developmental RNA processing program in neurodegeneration
Rachmian et al. Identification of senescent, TREM2-expressing microglia in aging and Alzheimer’s disease model mouse brain
Tournier et al. CCR5 deficiency: Decreased neuronal resilience to oxidative stress and increased risk of vascular dementia
WO2022126525A1 (fr) Marqueur prnp de maladie neurodégénérative et application associée
Shademan et al. MicroRNAs as a new target for Alzheimer's disease treatment
WO2023284035A1 (fr) Marqueur de maladie neurodégénérative et son application
Huang et al. High urea induces anxiety disorders associated with chronic kidney disease by promoting abnormal proliferation of OPC in amygdala
Wang et al. Upregulation of lncRNA147410. 3 in the brain of mice with chronic toxoplasma infection promoted microglia apoptosis by regulating Hoxb3
Matsumoto et al. An autopsy case of frontotemporal lobar degeneration with the appearance of fused in sarcoma inclusions (basophilic inclusion body disease) clinically presenting corticobasal syndrome
Vijayan et al. Unveiling the Role of Novel miRNA PC-5P-12969 in Alleviating Alzheimer’s Disease
CN113151432A (zh) 神经退行性疾病检测和治疗的新靶标
Li et al. CNTN1 Aggravates Neuroinflammation and Triggers Cognitive Deficits in Male Mice by Boosting Crosstalk between Microglia and Astrocytes
CN116559451B (zh) Fbxl20在抑郁症诊治中的应用
Zou et al. Long non‐coding RNA CASC15 enhances learning and memory in mice by promoting synaptic plasticity in hippocampal neurons

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20965541

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20965541

Country of ref document: EP

Kind code of ref document: A1